Rankings
▼
Calendar
CCCC
C4 Therapeutics, Inc.
$239M
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$21M
+10.4% YoY
Gross Profit
$21M
100.0% margin
Operating Income
-$35M
-165.8% margin
Net Income
-$34M
-159.5% margin
EPS (Diluted)
$-0.79
Cash Flow
Operating Cash Flow
$56M
Free Cash Flow
$54M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$118M
Total Liabilities
$230M
Stockholders' Equity
-$112M
Cash & Equivalents
$91M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$21M
$19M
+10.4%
Gross Profit
$21M
-$9M
+331.7%
Operating Income
-$35M
-$16M
-116.3%
Net Income
-$34M
-$16M
-117.0%
← FY 2018
All Quarters
Q1 2019 →
CCCC FY 2019 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena